诺和诺德：乐城引进帕西生长激素注射液，为GHD患儿提供新选择

Core Viewpoint - The introduction of Novo Nordisk's long-acting growth hormone, Pasi Growth Hormone Injection, at Boao Future Hospital provides a new treatment option for children with Growth Hormone Deficiency (GHD) in China, showing promising results in height increase within three months [1] Group 1: Product Introduction - Pasi Growth Hormone Injection has been introduced as a clinically needed drug and has already benefited over 20 children aged between 4.5 to 14.5 years with GHD [1] - The drug has demonstrated a height increase of 3-4 cm within three months of treatment [1] Group 2: Technology and Mechanism - The drug utilizes a mature technology known as fatty acid derivatization, which has been in use internationally for 36 years [1] - This technology involves single amino acid substitution in the GH molecule and reversible binding with endogenous albumin via fatty acid side chains, enhancing drug bioactivity and distribution [1] - The method allows for a prolonged half-life and sustained action, enabling administration only once a week [1] Group 3: Safety and Efficacy - The safety profile of Pasi Growth Hormone is supported by 7 years of clinical trials and real-world observations, indicating good safety characteristics [1] - The molecular structure of Pasi Growth Hormone is similar to that of human growth hormone, with metabolism primarily relying on the body's own albumin [1]